Department of Digestive Disease, Institut Mutualiste Montsouris, Université Paris Descartes, 42 Boulevard Jourdan, 75014, Paris, France.
Department of Digestive Surgery, Trousseau Hospital, Avenue de la République, 37170, Chambray-lès-Tours, France.
Surg Endosc. 2018 Dec;32(12):4788-4797. doi: 10.1007/s00464-018-6229-6. Epub 2018 May 14.
The major issue after liver resection for colorectal liver metastases (CRLM) is the high incidence of recurrence. Unlike open liver resection (OLR), recurrence following laparoscopic liver resection (LLR) is not well documented. The aim of this study was to analyze recurrence patterns and treatment following LLR for CRLM.
All patients who underwent LLR for CRLM from 2000 to 2016 were reviewed. Patients who presented with recurrence were compared to those who did not. Recurrence-free survival (RFS), overall survival (OS), and risk of recurrence and survival prognostic factors were analyzed.
Overall, 273 patients were included, of which 157 (57.5%) were treated for one liver metastasis (LM). Median follow-up was 41 (12-187) months and associated extrahepatic disease was present in 27% of patients (mainly pulmonary, 65%). After a median of 16 (3-151) months, 197 (72%) patients presented with recurrence. Recurrences were early (< 6 months) in 22.8% of cases, occured in a single site in 66% and were intrahepatic, extrahepatic, or both in 44, 30, and 26%, respectively. Recurrences were treated with surgery or chemotherapy only in 45 and 47%, respectively. 3-, 5-, and 10-year OS was 82, 71, and 43%, respectively. Independent risk factors for recurrence were node-positive primary tumor, extrahepatic disease before hepatectomy, and R1 resection.
LLR for CRLM does not seem to be associated with distinctive recurrence patterns. LLR for CRLM yielded satisfying RFS and OS and should therefore be considered whenever possible.
结直肠癌肝转移(CRLM)肝切除术后的主要问题是复发率高。与开腹肝切除术(OLR)不同,腹腔镜肝切除术(LLR)后的复发情况尚未得到充分记录。本研究旨在分析 LLR 治疗 CRLM 的复发模式和治疗方法。
回顾 2000 年至 2016 年间所有接受 LLR 治疗 CRLM 的患者。将复发患者与未复发患者进行比较。分析无复发生存期(RFS)、总生存期(OS)、复发和生存的风险因素。
共纳入 273 例患者,其中 157 例(57.5%)为单发肝转移(LM)。中位随访时间为 41 个月(12-187 个月),27%的患者存在肝外疾病(主要为肺部,65%)。中位随访 16 个月(3-151 个月)后,197 例(72%)患者出现复发。22.8%的复发发生在 6 个月内,66%的复发发生在单一部位,44%、30%和 26%的复发分别为肝内、肝外或两者均有。分别有 45%和 47%的患者仅接受手术或化疗治疗。3、5、10 年 OS 分别为 82%、71%和 43%。独立的复发危险因素包括原发肿瘤淋巴结阳性、肝切除术前肝外疾病和 R1 切除。
LR 治疗 CRLM 似乎与独特的复发模式无关。LR 治疗 CRLM 可获得令人满意的 RFS 和 OS,因此在可能的情况下应考虑使用。